Suppr超能文献

免疫抑制药物:硫唑嘌呤治疗重症肌无力

Immunosuppressive drugs: azathioprine in the treatment of myasthenia gravis.

作者信息

Matell G

机构信息

Myasthenia Gravis Center, Karolinska Institutet, South Hospital, Stockholm, Sweden.

出版信息

Ann N Y Acad Sci. 1987;505:589-94. doi: 10.1111/j.1749-6632.1987.tb51327.x.

Abstract

Azathioprine may be tried for treatment of severe myasthenia gravis, in a dose of 2 mg/kg BW. With careful monitoring the side reactions may be controlled. The therapeutic response will occur after a time delay of 4-8 months. About one-third of patients with type II MG (severe, late onset, HLA B8-) will proceed to a complete but azathioprine-dependent remission, and the remaining two-thirds to a marked improvement. In type I MG (early onset, HLA B8+) azathioprine is less effective but will help keep down the need for corticosteroids or plasmapheresis.

摘要

硫唑嘌呤可尝试用于治疗重症肌无力,剂量为2毫克/千克体重。通过仔细监测,副作用可以得到控制。治疗反应将在4至8个月的时间延迟后出现。约三分之一的II型重症肌无力患者(严重、迟发性、HLA B8阴性)将实现完全但依赖硫唑嘌呤的缓解,其余三分之二则会有明显改善。在I型重症肌无力患者(早发性、HLA B8阳性)中,硫唑嘌呤效果较差,但有助于减少对皮质类固醇或血浆置换的需求。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验